Emerging trends in colorectal cancer: Dysregulated signaling pathways (Review)
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Colorectal cancer (CRC) is the third most frequently detected type of cancer, and the second most common cause of cancer‑related mortality globally. The American Cancer Society predicted that approximately 147,950 individuals would be diagnosed with CRC, out of which 53,200 individuals would succumb to the disease in the USA alone in 2020. CRC‑related mortality ranks third among both males and females in the USA. CRC arises from 3 major pathways: i) The adenoma‑carcinoma sequence; ii) serrated pathway; and iii) the inflammatory pathway. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer. With widespread CRC screening, the incidence and mortality from CRC have decreased in developed countries. However, over the past few decades, CRC cases and mortality have been on the rise in young adults (age, <50 years). In addition, CRC cases are increasing in developing countries with a low gross domestic product (GDP) due to lifestyle changes. CRC is an etiologically heterogeneous disease classified by tumor location and alterations in global gene expression. Accumulating genetic and epigenetic perturbations and aberrations over time in tumor suppressor genes, oncogenes and DNA mismatch repair genes could be a precursor to the onset of colorectal cancer. CRC can be divided as sporadic, familial, and inherited depending on the origin of the mutation. Germline mutations in APC and MLH1 have been proven to play an etiological role, resulting in the predisposition of individuals to CRC. Genetic alterations cause the dysregulation of signaling pathways leading to drug resistance, the inhibition of apoptosis and the induction of proliferation, invasion and migration, resulting in CRC development and metastasis. Timely detection and effective precision therapies based on the present knowledge of CRC is essential for successful treatment and patient survival. The present review presents the CRC incidence, risk factors, dysregulated signaling pathways and targeted therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Mechanisms linking obesity to insulin resistance and type 2 diabetes
Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006) · Nature · doi:10.1038/nature05482 · Cited by 5,448
Renehan, A. G., Tyson, M., Egger, M., Heller, R. F., & Zwahlen, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60269-x · Cited by 5,219
Lessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
Genetic instabilities in human cancers
Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1998) · Nature · doi:10.1038/25292 · Cited by 4,168
Lichtenstein, P., Holm, N. V., Verkasalo, P. K., Iliadou, A., Kaprio, J., Koskenvuo, M., Pukkala, E., Skytthe, A., & Hemminki, K. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007133430201 · Cited by 4,114
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms
Calle, E. E., & Kaaks, R. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1408 · Cited by 3,613
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
VEGF receptor signalling ? in control of vascular function
Olsson, A.-K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1911 · Cited by 3,122
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915
Microsatellite Instability in Colorectal Cancer
Boland, C. R., & Goel, A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.064 · Cited by 2,456
Insulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059
Molecular Basis of Colorectal Cancer
Markowitz, S. D., & Bertagnolli, M. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804588 · Cited by 2,052
Immunotherapy in colorectal cancer: Rationale, challenges and potential
Ganesh, K., Stadler, Z. K., Cercek, A., Mendelsohn, R. B., Shia, J., Segal, N. H., & Diaz, L. A. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0126-x · Cited by 1,954
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Fluorinated pyrimidines, a new class of tumour-inhibitory compounds
HEIDELBERGER, C., CHAUDHURI, N. K., DANNEBERG, P., MOOREN, D., GRIESBACH, L., DUSCHINSKY, R., SCHNITZER, R. J., PLEVEN, E., & SCHEINER, J. (1957) · Nature · doi:10.1038/179663a0 · Cited by 1,603
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
Llosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0863 · Cited by 1,487
Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer)
Hampel, H., Frankel, W. L., Martin, E., Arnold, M., Khanduja, K., Kuebler, P., Nakagawa, H., Sotamaa, K., Prior, T. W., Westman, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043146 · Cited by 1,408
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
The Cancer Genome Atlas Research Network (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505917 · Cited by 1,336
Marcus, L., Lemery, S. J., Keegan, P., & Pazdur, R. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4070 · Cited by 1,176
Aune, D., Chan, D. S. M., Lau, R., Vieira, R., Greenwood, D. C., Kampman, E., & Norat, T. (2011) · BMJ · doi:10.1136/bmj.d6617 · Cited by 1,146
Microsatellite Instability in Colorectal Cancer-the Stable Evidence
Vilar, E., & Gruber, S. B. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.237 · Cited by 1,063
Kinase inhibitors: the road ahead
Ferguson, F. M., & Gray, N. S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.21 · Cited by 1,009
Tabernero, J., Yoshino, T., Cohn, A. L., Obermannova, R., Bodoky, G., Garcia-Carbonero, R., Ciuleanu, T.-E., Portnoy, D. C., Van Cutsem, E., Grothey, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70127-0 · Cited by 952
Meta-analyses of colorectal cancer risk factors
Johnson, C. M., Wei, C., Ensor, J. E., Smolenski, D. J., Amos, C. I., Levin, B., & Berry, D. A. (2013) · Cancer Causes & Control · doi:10.1007/s10552-013-0201-5 · Cited by 779
Obesity and Risk of Colorectal Cancer: A Systematic Review of Prospective Studies
Ma, Y., Yang, Y., Wang, F., Zhang, P., Shi, C., Zou, Y., & Qin, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053916 · Cited by 622
Association of Obesity With Risk of Early-Onset Colorectal Cancer Among Women
Liu, P.-H., Wu, K., Ng, K., Zauber, A. G., Nguyen, L. H., Song, M., He, X., Fuchs, C. S., Ogino, S., Willett, W. C., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4280 · Cited by 514
Kelly, D. M., & Jones, T. H. (2015) · Obesity Reviews · doi:10.1111/obr.12282 · Cited by 487
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
(2015) · New England Journal of Medicine · doi:10.1056/nejmc1510353 · Cited by 426
Rezende, L. F. M. D., Sá, T. H. D., Markozannes, G., Rey-López, J. P., Lee, I.-M., Tsilidis, K. K., Ioannidis, J. P. A., & Eluf-Neto, J. (2018) · British Journal of Sports Medicine · doi:10.1136/bjsports-2017-098391 · Cited by 276
The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy (Review)
Nguyen, H., & Duong, H. (2018) · Oncology Letters · doi:10.3892/ol.2018.8679 · Cited by 244
Martinelli, E., Ciardiello, D., Martini, G., Troiani, T., Cardone, C., Vitiello, P. P., Normanno, N., Rachiglio, A. M., Maiello, E., Latiano, T., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.007 · Cited by 225
Jeong, W.-J., Ro, E. J., & Choi, K.-Y. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0049-y · Cited by 220
Cancer incidence and mortality attributable to alcohol consumption
Praud, D., Rota, M., Rehm, J., Shield, K., Zatoński, W., Hashibe, M., La Vecchia, C., & Boffetta, P. (2016) · International Journal of Cancer · doi:10.1002/ijc.29890 · Cited by 218
Targeting TGF-β signaling in cancer
Katz, L. H., Li, Y., Chen, J.-S., Muñoz, N. M., Majumdar, A., Chen, J., & Mishra, L. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.782287 · Cited by 212
Guraya, S. Y. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i19.6026 · Cited by 179
The mitotic origin of chromosomal instability
Bakhoum, S. F., Silkworth, W. T., Nardi, I. K., Nicholson, J. M., Compton, D. A., & Cimini, D. (2014) · Current Biology · doi:10.1016/j.cub.2014.01.019 · Cited by 142
Estrogen metabolism in abdominal subcutaneous and visceral adipose tissue in postmenopausal women
Hetemäki, N., Savolainen-Peltonen, H., Tikkanen, M. J., Wang, F., Paatela, H., Hämäläinen, E., Turpeinen, U., Haanpää, M., Vihma, V., & Mikkola, T. S. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01474 · Cited by 140
The role of the PI3K pathway in colorectal cancer
Papadatos-Pastos, D., Rabbie, R., Ross, P., & Sarker, D. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.12.006 · Cited by 126
Rise of PD-L1 expression during metastasis of colorectal cancer: Implications for immunotherapy
Wang, H. B., Yao, H., Li, C. S., Liang, L. X., Zhang, Y., Chen, Y. X., Fang, J., & Xu, J. (2017) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12538 · Cited by 100
Hedgehog signaling pathway in colorectal cancer: function, mechanism, and therapy
Wu, C., Zhu, X., Liu, W., Ruan, T., & Tao, K. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s139639 · Cited by 82
Cited by
Recent advances in targeted drug delivery systems for resistant colorectal cancer
Sharifi-Azad, M., Fathi, M., Cho, W. C., Barzegari, A., Dadashi, H., Dadashpour, M., & Jahanban-Esfahlan, R. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02605-y · Cited by 65
Advances in Chitosan-Based Smart Hydrogels for Colorectal Cancer Treatment
Piotrowska, U., & Orzechowska, K. (2024) · Pharmaceuticals · doi:10.3390/ph17101260 · Cited by 30
Feng, Y., Wang, K., Fan, J., Wu, X., Li, T., & Yang, Z. (2024) · BMC Cancer · doi:10.1186/s12885-024-12508-y · Cited by 26
“The solution-focused mode is characterized by fully respecting individual resources and potential, and emphasizing that the focus of problem-solving is on the positive aspects of people [6].”
An updated landscape on nanopharmaceutical delivery for mitigation of colon cancer
Shahzad, M., Hameed, H., Amjad, A., Khan, M. A., Qureshi, I. S., Hameed, A., Saeed, A., & Munir, R. (2025) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-024-03482-0 · Cited by 7
Metadata
- Authors
- Ahmad, R., Singh, J., Wunnava, A., Al‑Obeed, O., Abdulla, M., & Srivastava, S.
- Venue
- International Journal of Molecular Medicine
- Publisher
- Spandidos Publications
- Published
- 2021-01-07
- Volume
- 47
- Issue
- 3
- ISSN
- 1107-3756 (ISSN-L)
- 1791-244X
- OpenAlex
- W3119040569
- Cited by
- 189
- References
- 49
- FWCI
- 15.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.